CN116096353A - 异二聚体fc融合蛋白的配制品、剂量方案和制造工艺 - Google Patents

异二聚体fc融合蛋白的配制品、剂量方案和制造工艺 Download PDF

Info

Publication number
CN116096353A
CN116096353A CN202180042458.1A CN202180042458A CN116096353A CN 116096353 A CN116096353 A CN 116096353A CN 202180042458 A CN202180042458 A CN 202180042458A CN 116096353 A CN116096353 A CN 116096353A
Authority
CN
China
Prior art keywords
pharmaceutical formulation
heterodimeric
fusion protein
region
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180042458.1A
Other languages
English (en)
Chinese (zh)
Inventor
M·毕格罗
A·布劳恩
A·F·张
J-M·库列罗
M·德罗斯
A·格林贝格
E·古铁雷斯
P·科比
C·R·摩根
M·C·奈尔
S·奥尼尔
M·希夫林
N·瓦特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dragonfly Therapy Co ltd
Original Assignee
Dragonfly Therapy Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dragonfly Therapy Co ltd filed Critical Dragonfly Therapy Co ltd
Publication of CN116096353A publication Critical patent/CN116096353A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN202180042458.1A 2020-04-22 2021-04-22 异二聚体fc融合蛋白的配制品、剂量方案和制造工艺 Pending CN116096353A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063013834P 2020-04-22 2020-04-22
US63/013,834 2020-04-22
US202063033161P 2020-06-01 2020-06-01
US63/033,161 2020-06-01
PCT/US2021/028701 WO2021216916A1 (en) 2020-04-22 2021-04-22 Formulation, dosage regimen, and manufacturing process for heterodimeric fc-fused proteins

Publications (1)

Publication Number Publication Date
CN116096353A true CN116096353A (zh) 2023-05-09

Family

ID=75919398

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180042458.1A Pending CN116096353A (zh) 2020-04-22 2021-04-22 异二聚体fc融合蛋白的配制品、剂量方案和制造工艺

Country Status (10)

Country Link
US (1) US20230272041A1 (enExample)
EP (1) EP4138778A1 (enExample)
JP (2) JP7644777B2 (enExample)
KR (1) KR20230004746A (enExample)
CN (1) CN116096353A (enExample)
AU (1) AU2021260960A1 (enExample)
CA (1) CA3175809A1 (enExample)
IL (1) IL297495A (enExample)
MX (1) MX2022013112A (enExample)
WO (1) WO2021216916A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092987A1 (zh) * 2023-11-03 2025-05-08 拓济医药（苏州）有限责任公司 基于Fc区的异二聚体分子及其用途

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202007482WA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Antibody variable domains targeting the nkg2d receptor
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
JP7235770B2 (ja) 2018-05-10 2023-03-08 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤
EP3833385A4 (en) 2018-08-08 2021-12-22 Dragonfly Therapeutics, Inc. PROTEINS THAT BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN
EP3833392A4 (en) 2018-08-08 2022-05-18 Dragonfly Therapeutics, Inc. MULTISPECIFIC BINDING PROTEINS FOR BINDING CD33, NKG2D AND CD16 AND METHODS OF USE
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
MX2021003543A (es) 2018-09-27 2021-06-23 Xilio Dev Inc Polipeptidos de citocinas enmascaradas.
CN115836088A (zh) 2020-05-06 2023-03-21 蜻蜓疗法股份有限公司 结合nkg2d、cd16和clec12a的蛋白质
JP2023553323A (ja) 2020-11-25 2023-12-21 エクシリオ デベロップメント， インコーポレイテッド 腫瘍特異的に切断可能なリンカー
WO2022187539A1 (en) 2021-03-03 2022-09-09 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen
EP4419545A4 (en) 2021-10-20 2025-10-22 Synthekine Inc HETERODIMERIC FC CYTOKINES AND THEIR USES
CN115575467A (zh) * 2022-09-30 2023-01-06 华润生物医药有限公司 一种检测重组人GLP-1-Fc融合蛋白的方法
WO2024086739A1 (en) 2022-10-20 2024-04-25 Synthekine, Inc. Methods and compositions of il12 muteins and il2 muteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019051308A1 (en) * 2017-09-07 2019-03-14 Dragonfly Therapeutics, Inc. NKG2D, CD16 BINDING PROTEINS AND ANTIGEN ASSOCIATED WITH A TUMOR
CN110214147A (zh) * 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
GB9022040D0 (en) 1990-10-10 1990-11-21 Biopharm Ltd Platelet adhesion inhibitor
US5851794A (en) 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
EP0635029A4 (en) 1992-04-10 1996-01-24 Gen Hospital Corp MATRIX PROTEIN FROM CARTILAGE AND APPLICATION METHODS.
US5491130A (en) 1992-11-10 1996-02-13 The United States Of America As Represented By The Department Of Health And Human Services Peptide inhibitors of fibronectin and related collagen-binding proteins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
CA2255669A1 (en) 1996-05-16 1997-11-20 The Texas A & M University System Collagen binding protein compositions and methods of use
US6387663B1 (en) 1998-07-31 2002-05-14 University Of Southern California Targeting pharmaceutical agents to injured tissues
WO2000021989A1 (en) 1998-10-09 2000-04-20 Medimmune, Inc. Decorin binding proteins dbp a and b and genes encoding them
JP2003500011A (ja) 1999-03-15 2003-01-07 ザ・ジェネラル・ホスピタル・コーポレイション シンデスモスおよびその利用法
US6864235B1 (en) 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6908994B1 (en) 1999-05-10 2005-06-21 The Texas A&M University System Collagen-binding proteins from enterococcal bacteria
WO2000077041A2 (en) 1999-06-16 2000-12-21 The Texas A & M University System Peptides from decorin binding protein and their uses
AU5622800A (en) 1999-06-18 2001-01-09 Med Immune, Inc. Combined decorin binding protein and outer surface protein compositions and methods of use
NZ519546A (en) 1999-12-15 2005-07-29 Res Dev Foundation Betaglycan as an inhibin receptor and uses thereof
US6777547B1 (en) 2000-01-31 2004-08-17 Andreas Podbielski Collagen-binding proteins from streptococcus pyogenes
US6517838B1 (en) 2000-06-16 2003-02-11 The Texas A&M University System Decorin binding protein essential peptides and methods of use
AU2001292943A1 (en) 2000-09-21 2002-04-02 The Brigham And Women's Hospital, Inc. Prevention and treatment of streptococcal and staphylococcal infection
EP1411118B1 (en) 2001-06-22 2008-09-03 Chugai Seiyaku Kabushiki Kaisha Cell proliferation inhibitors containing anti-glypican-3 antibody
US8192744B2 (en) 2002-08-26 2012-06-05 Ibcc Holding As Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation
US7488792B2 (en) 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
GB0406415D0 (en) 2004-03-22 2004-04-21 Inst Of Cancer Res The Materials and methods for treatment of cancer
JP4730304B2 (ja) 2004-05-20 2011-07-20 和光純薬工業株式会社 ヒアルロン酸バインディングプロテインを用いたヒアルロン酸の測定方法
CA2565405A1 (en) 2004-06-18 2005-12-29 F. Hoffmann-La Roche Ag Use of protein cbp2 as a marker for colorectal cancer
CA2544692C (en) 2004-07-09 2014-04-01 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody
WO2006023382A2 (en) 2004-08-23 2006-03-02 Albert Einstein College Of Medicine Of Yeshiva University Collagen vi and cancer
US20090142345A1 (en) 2005-03-15 2009-06-04 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
CA2610791C (en) 2005-06-08 2015-12-01 Cangene Corporation Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
EP1864996A1 (en) 2006-06-06 2007-12-12 Helmholtz-Zentrum für Infektionsforschung GmbH Peptide associated with rheumatic fever (PARF) and its use as a diagnostic marker.
HU0600578D0 (en) 2006-07-13 2006-09-28 Szilak Labor Bioinformatikai E Nuclear protein transport
JP5466405B2 (ja) 2006-08-08 2014-04-09 生化学工業株式会社 ヒアルロン酸の分子量の測定方法
DK2178921T3 (en) 2007-07-17 2016-04-04 Squibb & Sons Llc Monoclonal antibodies to glypican 3
KR20110005812A (ko) 2008-03-17 2011-01-19 고쿠리츠 다이가쿠 호징 미야자키 다이가쿠 항-글리피칸-3 항체를 사용하여 간암 세포를 검출하는 방법
US20090297479A1 (en) 2008-03-28 2009-12-03 Kiyoshi Ariizumi Dc-hil conjugates for treatment of t-cell disorders
HUE029925T2 (en) 2008-04-02 2017-04-28 Macrogenics Inc HER2 / neu-specific antibodies and methods using them
US8034630B2 (en) 2008-04-15 2011-10-11 Wako Pure Chemical Industries, Ltd. Protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same
WO2010033866A2 (en) 2008-09-19 2010-03-25 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma
GB0818273D0 (en) 2008-10-06 2008-11-12 Cambridge Entpr Ltd Modulation of cellular activity and differentiation
KR101105428B1 (ko) 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
WO2010129547A1 (en) 2009-05-04 2010-11-11 Purdue Research Foundation Collagen-binding synthetic peptidoglycans for wound healing
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
SG10201508401TA (en) * 2010-10-11 2015-11-27 Abbvie Bahamas Ltd Processes for purification of proteins
US9260492B2 (en) 2010-11-15 2016-02-16 Pieris Ag Muteins of human lipocalin 2 with affinity for glypican-3 (GPC-3)
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
ES2692268T5 (en) 2011-03-29 2025-02-26 Roche Glycart Ag Antibody fc variants
WO2012145469A1 (en) 2011-04-19 2012-10-26 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for glypican-3 and use thereof
EP2714718B1 (en) 2011-05-24 2017-01-11 Symic IP, LLC Hyaluronic acid-binding synthetic peptidoglycans, preparation, and methods of use
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
US9795686B2 (en) 2012-01-19 2017-10-24 The Johns Hopkins University Biomaterials comprising hyaluronic acid binding peptides and bifunctional biopolymer molecules for hyaluronic acid retention and tissue engineering applications
WO2013163766A1 (en) 2012-05-04 2013-11-07 Cangene Corporation ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC
US9522940B2 (en) 2012-05-23 2016-12-20 Pieris Pharmaceuticals Gmbh Lipocalin muteins with binding-affinity for glypican-3 (GPC-3) and use of lipocalin muteins for target-specific delivery to cells expressing GPC-3
US9409994B2 (en) 2012-06-01 2016-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High-affinity monoclonal antibodies to glypican-3 and use thereof
US10093745B2 (en) 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
US20160032007A1 (en) 2014-04-28 2016-02-04 Duke University Human Antibody Fragments Against Chondroitin Sulfate Proteoglycan 4 (CSPG4)
WO2015197593A1 (en) 2014-06-27 2015-12-30 Innate Pharma MULTISPECIFIC NKp46 BINDING PROTEINS
WO2016007919A2 (en) 2014-07-11 2016-01-14 Regents Of The University Of Minnesota Antibody fragments for detecting cancer and methods of use
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US11091547B2 (en) 2014-11-12 2021-08-17 Memorial Sloan Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
JP6920207B2 (ja) 2015-03-20 2021-08-18 オルブセン セラピューティクス リミテッド シンデカン−２のモジュレーターとその使用
US10881711B2 (en) 2015-04-06 2021-01-05 The General Hospital Corporation Anti-CSPG4 reagents and methods of treating cancer
KR20180033502A (ko) * 2015-06-12 2018-04-03 알렉터 엘엘씨 항-cd33 항체 및 그의 사용 방법
JP6762485B2 (ja) 2015-06-24 2020-09-30 学校法人慶應義塾 抗グリピカン−１−免疫抗原受容体
EP3349770A1 (en) 2015-09-14 2018-07-25 Regents of the University of Minnesota Nk cells exhibiting an adaptive phenotype and methods for preparing and for using
EP3353198B1 (en) 2015-09-23 2020-06-17 Bristol-Myers Squibb Company Glypican-3binding fibronectin based scafflold molecules
EP3359168A4 (en) 2015-10-06 2019-08-07 Regents of the University of Minnesota THERAPEUTIC COMPOUNDS AND METHOD
KR101796688B1 (ko) 2015-10-29 2017-12-01 재단법인 목암생명과학연구소 신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
US11066479B2 (en) 2016-08-02 2021-07-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof
KR102050463B1 (ko) * 2016-08-10 2019-11-29 아주대학교산학협력단 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물
CN110831634B (zh) 2017-03-08 2024-07-02 密歇根大学董事会 磷脂酰肌醇蛋白聚糖-3肽试剂和方法
EP3615573A4 (en) 2017-04-26 2021-01-20 Mitsubishi Tanabe Pharma Corporation SYNDECAN-1 (CD138) BINDING AGENTS AND THEIR USES
US20200308299A1 (en) 2017-04-28 2020-10-01 National University Corporation Kochi University Anti-gpc-1 antibody
US11547957B2 (en) * 2017-05-11 2023-01-10 Emd Millipore Corporation Method of maintaining narrow residence time distributions in continuous flow systems
WO2018237159A1 (en) * 2017-06-21 2018-12-27 Cephalon, Inc. Cation exchange chromatography wash buffer
SG11202007579TA (en) 2018-02-08 2020-09-29 Dragonfly Therapeutics Inc Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
SG11202103192RA (en) * 2018-10-03 2021-04-29 Xencor Inc Il-12 heterodimeric fc-fusion proteins
CA3117212A1 (en) * 2018-10-23 2020-04-30 Dragonfly Therapeutics, Inc. Heterodimeric fc-fused proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110214147A (zh) * 2016-10-14 2019-09-06 Xencor股份有限公司 IL15/IL15Rα异源二聚体FC-融合蛋白
WO2019051308A1 (en) * 2017-09-07 2019-03-14 Dragonfly Therapeutics, Inc. NKG2D, CD16 BINDING PROTEINS AND ANTIGEN ASSOCIATED WITH A TUMOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JUNG, K ET AL.: "Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8+ T cells", 《ONCOIMMUNOLOGY》, vol. 7, no. 7, 6 March 2018 (2018-03-06), pages 1438800 - 1 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025092987A1 (zh) * 2023-11-03 2025-05-08 拓济医药（苏州）有限责任公司 基于Fc区的异二聚体分子及其用途

Also Published As

Publication number Publication date
JP7644777B2 (ja) 2025-03-12
WO2021216916A1 (en) 2021-10-28
AU2021260960A1 (en) 2022-11-24
MX2022013112A (es) 2023-01-16
KR20230004746A (ko) 2023-01-06
US20230272041A1 (en) 2023-08-31
IL297495A (en) 2022-12-01
JP2023522972A (ja) 2023-06-01
JP2025037910A (ja) 2025-03-18
CA3175809A1 (en) 2021-10-28
EP4138778A1 (en) 2023-03-01

Similar Documents

Publication Publication Date Title
JP7644777B2 (ja) ヘテロ二量体Ｆｃ融合タンパク質のための製剤、投薬量レジメン、及び製造工程
TWI891611B (zh) 異二聚體fc融合蛋白
JP7369297B2 (ja) Ｃｄ４７、ｐｄ－ｌ１に特異的な抗体、およびその使用
US20220195065A1 (en) Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatment
JP2021176880A (ja) Ｉｌ−１５ベース分子及びその使用方法
CN113056285A (zh) 抗肿瘤免疫检查点调节剂拮抗剂
CN112533944A (zh) 多特异性结合蛋白及其改进
US20180147257A1 (en) Btn3a ectodomain proteins and methods of use
JP2024167278A (ja) Ｉｌ－７タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
US20240209061A1 (en) Fusion proteins and uses thereof
CA3122914A1 (en) Bifunctional anti-pd-1/sirp.alpha. molecule
WO2023107956A1 (en) Proteins binding nkg2d, cd16 and 5t4
WO2022245671A1 (en) Methods of using flt3l-fc fusion proteins
TW201208703A (en) Combination therapy of an afucosylated CD20 antibody with an anti-VEGF antibody
KR20240099362A (ko) 혈액암에 대한 lag-3 길항제 요법
KR20230066586A (ko) 암을 위한 병용 요법
US11773160B1 (en) Immune-stimulating IL-2 fusion proteins
HK40056403A (en) Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
EA046081B1 (ru) Мультиспецифические связывающие белки и их усовершенствования
HK40019175B (en) Cd70 binding molecules and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230509